Impact of SARS-CoV-2 Vaccination on Disease Activity and Severity of COVID-19 Infection in Patients with Systemic Lupus Erythematosus: A Multicenter Cohort Study

Vaccination against SARS-CoV-2 demonstrated a favorable safety profile in patients with SLE, with a low frequency of serious adverse events. While analysis of disease activity revealed variations across vaccine platforms, most notably an increased proportion of moderate to high disease activity among those receiving ChAdOx-1 compared with CoronaVac and BNT162b2, the overall occurrence of COVID-19 during follow-up was limited to mild cases, with no severe outcomes. These findings highlight that, despite potential risks of disease exacerbation, the clear protection against severe COVID-19 supports vaccination as a beneficial strategy for this immunocompromised population.

Authors

Institutions

Publication Details

Journal
Vaccines
Published
2025-10-21
DOI
https://doi.org/10.3390/vaccines13101074
Primary Topic
Systemic Lupus Erythematosus Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Impact of SARS-CoV-2 Vaccination on Disease Activity and Severity of COVID-19 Infection in Patients with Systemic Lupus Erythematosus: A Multicenter Cohort Study

Viviane Angelina de Souza, Rodrigo Cutrim Gaudio, Erika Biegelmeyer, F Pretti et al.
Vaccines
Systemic Lupus Erythematosus Research
article

Impact of SARS-CoV-2 Vaccination on Disease Activity and Severity of COVID-19 Infection in Patients with Systemic Lupus Erythematosus: A Multicenter Cohort Study

Viviane Angelina de Souza, Rodrigo Cutrim Gaudio, Erika Biegelmeyer, F Pretti, Bruna Guimarães Dutra, Jozélia Rêgo, Natália Sarzi Sartori, Emília Inoue Sato, Gilda Aparecida Ferreira, Alexandre Wagner Silva de Souza, Valderílio Feijó Azevedo, Valéria Valim, Vanessa Peruhype-Magalhães, Vítor Alves Cruz, Cristiane Kayser, Marcos Mavignier Sousa Dias, Ketty Lysie Libardi Lira Machado, Paula dos Santos Athayde, Luiza Lorenzoni Grillo, J. Rodrigues, Mariana Freitas de Aguiar, Sérgio Henrique Oliveira dos Santos, Camila Maria Paiva França Telles, Vanessa de Oliveira Magalhães, Gecilmara Salviato Pileggi, Priscila Dias Cardoso Ribeiro, Odirlei André Monticielo, Samira Tatiyama Miyamoto, Helena da Silva Corona, Charlles Heldan de Moura Castro, Maria da Penha Gomes Gouvea, Adriana María Kakehasi, Flávia Maria Matos Melo Campos Peixoto, Ana Paula Neves Burian, Samuel Elias Basualto Dias, Adah Sophia Rodrigues Vieira, Marcelo M. Pinheiro, Sandra Lúcia Euzébio Ribeiro, Rodrigo Poubel Vieira de Rezende, Ana Karla Guedes de Melo, Juliana Bühring, Filipe Faé, Valéria Bezerra da Silva, Ricardo Machado Xavier, Edgard Torres dos Reis-Neto, Rejane Maria Rodrigues de Abreu Vieira, Kátia Lino, Clara Pinheiro Martins, Anna Carolina Faria Moreira Gomes Tavares, Andréa Teixeira-Carvalho, Naieli Andrade, Olindo Assis Martins-Filho, Vasco Silva, Alexandre C. Pereira, Sabrina de Souza Ramos, Guilherme Leví Tres, Karina Rosemarie Lallemand Tapia, Anna Carolina Simões Moulin, Yasmin Gurtler Pinheiro de Oliveira, Pollyana Vitoria Thomaz da Costa
article en

Abstract

Vaccination against SARS-CoV-2 demonstrated a favorable safety profile in patients with SLE, with a low frequency of serious adverse events. While analysis of disease activity revealed variations across vaccine platforms, most notably an increased proportion of moderate to high disease activity among those receiving ChAdOx-1 compared with CoronaVac and BNT162b2, the overall occurrence of COVID-19 during follow-up was limited to mild cases, with no severe outcomes. These findings highlight that, despite potential risks of disease exacerbation, the clear protection against severe COVID-19 supports vaccination as a beneficial strategy for this immunocompromised population.

VaccinesVol. 13(10)
Universidade Federal de Juiz de Fora (BR), Universidade Federal de Minas Gerais (BR), Universidade Federal do Rio Grande do Sul (BR), Universidade Federal Fluminense (BR), Universidade Federal da Paraíba (BR), Universidade de Fortaleza (BR), Hospital de Clínicas de Porto Alegre (BR), Hospital Universitário Lauro Wanderley (BR), Instituto de Saúde (BR), Hospital das Clínicas da Universidade Federal de Minas Gerais (BR), Secretaria da Saúde (BR), Universidade Federal do Espírito Santo (BR), Fundação Oswaldo Cruz (BR), Universidade Federal do Amazonas (BR), Universidade Federal de Goiás (BR), Universidade Federal de São Paulo (BR)
Openalex Percentile: Top 57%
Systemic Lupus Erythematosus Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.